Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 09/15/20
End: 06/29/21
Due: 06/29/22
Phase: N/A
Priority: Normal
Start: 03/04/20
End: 08/05/24
Due: 08/05/25
Phase: N/A
Priority: Normal
Start: 08/31/25
End: 05/31/29
Due: 05/31/30
Phase: N/A
Priority: Normal
Start: 08/23/17
End: 05/30/19
Due: 05/30/20
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation | NCT04452669 | Aerogen Pharma Limited | user2@example.com | None | 2020-09-15 | 2021-06-29 | 2022-06-29 | - | - | 2025-07-14 |
| A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact | NCT03969992 | Aerogen Pharma Limited | user2@example.com | None | 2020-03-04 | 2024-08-05 | 2025-08-05 | - | - | 2025-07-14 |
| Safety and Efficacy of AeroFact in Preterm Infants With Respiratory Distress Syndrome | NCT06776783 | Aerogen Pharma Limited | user2@example.com | None | 2025-08-31 | 2029-05-31 | 2030-05-31 | - | - | 2025-07-14 |
| VentaProst Versus Conventionally-Administered Aerosolized Epoprostenol in Patients Undergoing Cardiac Surgery With CPB | NCT03122730 | Aerogen Pharma Limited | user2@example.com | None | 2017-08-23 | 2019-05-30 | 2020-05-30 | - | - | 2025-07-14 |